SYM vs. VRNA

Last updated Jun 16, 2026

SYM (Symbotic Inc) and VRNA (Verona Pharma plc) are both stocks. SYM operates in Specialty Industrial Machinery (Industrials), while VRNA operates in Biotechnology (Healthcare). At a 0.16 correlation, their price movements are largely independent.

Performance

SYM vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Symbotic Inc (SYM) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

SYM

• 1D: 0.22%
• 1M: -11.83%
• YTD: -29.88%
• 6M: -30.15%
• 1Y: 49.16%
• 3Y*: -6.61%
• 5Y*: 33.12%
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SYM vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SYM Symbotic Inc	-29.88%	150.95%	-53.81%	329.90%	19.40%	-3.38%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-23.64%

Correlation

The correlation between SYM and VRNA is -0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.08
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.16
Correlation (All Time) Calculated using the full available price history since Mar 9, 2021	0.16

The correlation between SYM and VRNA shifts across timeframes, from -0.08 (1 year) to 0.17 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap SYM : $5.61B VRNA : $9.72B
EPS SYM : $0.09 VRNA : -$0.69
PS Ratio SYM : 2.00 VRNA : 57.97
PB Ratio SYM : 5.45 VRNA : 34.92
Total Revenue (TTM) SYM : $2.52B VRNA : $167.65M
Gross Profit (TTM) SYM : $501.51M VRNA : $159.52M
EBITDA (TTM) SYM : $16.80M VRNA : -$40.86M

Return for Risk

SYM vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYM

SYM Risk / Return Rank: 62
SYM Sharpe Ratio Rank: 61
SYM Sortino Ratio Rank: 66
SYM Omega Ratio Rank: 63
SYM Calmar Ratio Rank: 62
SYM Martin Ratio Rank: 60

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SYM vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Symbotic Inc (SYM) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SYM	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	0.54	—	—
Sortino ratio: Return per unit of downside risk	1.43	—	—
Omega ratio: Gain probability vs. loss probability	1.17	—	—
Calmar ratio: Return relative to maximum drawdown	0.94	—	—
Martin ratio: Return relative to average drawdown	1.72	—	—

Drawdowns

Drawdown Indicators

	SYM	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-72.46%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-52.76%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-72.46%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-72.46%	—	—
Current Drawdown Current decline from peak	-52.21%	—	—
Average Drawdown Average peak-to-trough decline	-28.13%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	28.71%	—	—

Volatility

Volatility by Period

	SYM	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.58%	—	—
Volatility (6M) Calculated over the trailing 6-month period	44.39%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	90.84%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	104.19%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	101.49%	—	—

Dividends

SYM vs. VRNA - Dividend Comparison

Neither SYM nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

SYM vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Symbotic Inc and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SYM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Symbotic Inc reported a gross profit of 149.95M and revenue of 676.48M. Therefore, the gross margin over that period was 22.2%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

SYM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Symbotic Inc reported an operating income of 6.09M and revenue of 676.48M, resulting in an operating margin of 0.9%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

SYM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Symbotic Inc reported a net income of 17.52M and revenue of 676.48M, resulting in a net margin of 2.6%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both SYM and VRNA in my portfolio?

SYM and VRNA have a correlation of -0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.